Disulfide re-bridging reagents for single-payload antibody-drug conjugates
- PMID: 37492000
- PMCID: PMC10414422
- DOI: 10.1039/d3cc02980h
Disulfide re-bridging reagents for single-payload antibody-drug conjugates
Abstract
Numerous antibody-drug conjugate (ADC) linker technologies exist for the synthesis of ADCs with drug-to-antibody ratios (DARs) being an even integer (typically 2, 4 or 8). However, ADCs with odd-integer DARs are significantly harder to synthesise. Here, we report the synthesis of ADCs loaded with a single warhead, using TetraDVP linkers which simultaneously re-bridge all four interchain disulfides of an IgG1 antibody.
Conflict of interest statement
S. J. W. and D. R. S. are inventors on a patent application covering the compounds reported in this communication.
Figures




References
-
- ImmunoGen, ImmunoGen Announces FDA Accelerated Approval of ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer, https://investor.immunogen.com/news-releases/news-release-details/immuno..., (accessed 29 January 2023)
-
- Van Delft F. L., Van Geel R. and Wijdeven M. A., European Pat., EP2911699B1, 2017
MeSH terms
Substances
LinkOut - more resources
Full Text Sources